KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Long-Term Deferred Tax rose 2178.99% to $2.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 2178.99%. This contributed to the annual value of $2.2 billion for FY2025, which is 2178.99% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Long-Term Deferred Tax stood at $2.2 billion, which was up 2178.99% from $1.6 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Long-Term Deferred Tax ranged from a high of $2.2 billion in Q4 2025 and a low of $596.0 million during Q4 2021
  • Over the past 5 years, Teva Pharmaceutical Industries' median Long-Term Deferred Tax value was $1.6 billion (recorded in 2022), while the average stood at $1.5 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Long-Term Deferred Tax surged by 14855.31% in 2022 and then tumbled by 2106.28% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Long-Term Deferred Tax (Quarter) stood at $596.0 million in 2021, then skyrocketed by 144.63% to $1.5 billion in 2022, then increased by 24.28% to $1.8 billion in 2023, then decreased by 0.72% to $1.8 billion in 2024, then rose by 21.79% to $2.2 billion in 2025.
  • Its last three reported values are $2.2 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.8 billion during Q2 2025.